Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus ...Middle East

Medscape - News
Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib in a new trial shows that efficacy extends to cutaneous lupus. Medscape Medical News

Hence then, the article about phase 2 trial supports tyk2 inhibitor for cutaneous lupus was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News